232 related articles for article (PubMed ID: 26338274)
21. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
22. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
Macias-Perez IM; Flinn IW
Curr Hematol Malig Rep; 2013 Mar; 8(1):22-7. PubMed ID: 23114654
[TBL] [Abstract][Full Text] [Related]
23. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
24. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
25. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
26. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
27. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Fiorcari S; Brown WS; McIntyre BW; Estrov Z; Maffei R; O'Brien S; Sivina M; Hoellenriegel J; Wierda WG; Keating MJ; Ding W; Kay NE; Lannutti BJ; Marasca R; Burger JA
PLoS One; 2013; 8(12):e83830. PubMed ID: 24376763
[TBL] [Abstract][Full Text] [Related]
28. Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor.
Munakata W; Tobinai K
Lancet Haematol; 2018 Apr; 5(4):e134-e135. PubMed ID: 29550380
[No Abstract] [Full Text] [Related]
29. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Davids MS; Brown JR
Hematol Oncol Clin North Am; 2013 Apr; 27(2):329-39. PubMed ID: 23561476
[TBL] [Abstract][Full Text] [Related]
30. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
32. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
33. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract][Full Text] [Related]
35. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
Crassini K; Shen Y; O'Dwyer M; O'Neill M; Christopherson R; Mulligan S; Best OG
Br J Haematol; 2018 Sep; 182(5):654-669. PubMed ID: 29978459
[TBL] [Abstract][Full Text] [Related]
36. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
[TBL] [Abstract][Full Text] [Related]
38. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
40. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]